# WORK Medical Technology Group LTD > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/WORK Medical Technology Group LTD). ## Overview WORK Medical Technology Group LTD is a medical device company with operating subsidiaries in China that develops and manufactures Class I and II medical devices and sells disposable medical products. Its portfolio includes masks and other medical consumables, and the group also markets anesthesia and respiratory consumables through its medical device line. ## Products & services • Class I and II medical devices • Disposable medical consumables • Customized and multifunctional masks • Anesthesia consumables • Respiratory consumables • Limited commodity trading activities - **Medical devices** (92%) — Self-manufactured medical devices, mainly anesthesia and respiratory consumables. - **Masks** (8%) — Disposable and customized mask products sold through the company’s China operations. - **Commodity trading** (0%) — Small-scale trading of products outside the core medical device portfolio. - **Other products** (0%) — Minor residual sales not classified within the main product lines. - Class I and II medical devices - Disposable medical consumables - Customized and multifunctional masks - Anesthesia consumables - Respiratory consumables - Limited commodity trading activities ## Customers The company sells primarily to distributor customers and direct end users, with credit terms varying by customer relationship and creditworthiness. Its products serve medical channels that need disposable consumables, masks, and anesthesia or respiratory supplies, with sales in China and selected overseas markets. - **Distributors** (primary) — Buy medical devices and consumables for resale into local medical supply channels. - **Direct end users** (primary) — Purchase products directly for use in care delivery or operations. - **Healthcare institutions** (secondary) — Hospitals and clinics buy anesthesia and respiratory consumables for routine use. - **Overseas buyers** (secondary) — International customers purchase approved products through export channels. - Distributor customers buying for resale into medical channels - Direct end users needing disposable medical supplies - Hospitals and clinics purchasing anesthesia/respiratory consumables - Overseas customers served through export and distribution channels - Customers that value approved, standardized medical consumables ## Geography WORK Medical’s core operating base is in China, where it sells across 34 provincial-level administrative regions. It also sells overseas and has registered products with the U.S. FDA, supporting access to the U.S. market and broader international distribution. - **China domestic market** (79.1%) — Six months ended March 31, 2026 - **Overseas market** (20.9%) — Six months ended March 31, 2026 - China is the main sales market and operating base - Sales span 34 provincial-level administrative regions in China - Overseas sales are an important secondary market - A U.S. subsidiary supports direct U.S. commercial presence - FDA registrations support entry into the U.S. market ## Strategy The company is building a more direct international platform by establishing a U.S. subsidiary to support supply-chain management, customer engagement, and regulatory execution. Its broader strategy is to extend its medical-device portfolio beyond China while using FDA-registered products and existing manufacturing capabilities to support export growth. - **U.S. market build-out** (short-term) — A direct U.S. presence can improve customer access, market development, and operational control. - **International expansion** (medium-term) — Diversifying beyond China can broaden the addressable market and reduce dependence on one geography. - **Regulatory and market access** (medium-term) — FDA registrations and compliance capabilities are essential to selling in regulated medical markets. - Build a direct U.S. commercial platform - Strengthen international distribution and customer engagement - Use FDA registrations to expand market access - Support supply-chain and regulatory execution across markets - Broaden global footprint beyond the China core ## Risks The business depends on regulatory approvals, product quality, and the ability to collect receivables from distributors and end users. It also faces execution risk in expanding outside China, where local market access, supply-chain coordination, and compliance requirements can affect growth and operating stability. - **Receivable collectability** [high] — The company grants 30 to 180 days of credit, increasing exposure to delayed payment or default. - **Product quality and recalls** [high] — Medical devices and consumables are subject to quality objections and third-party testing. - **Regulatory and market access** [high] — Medical device sales depend on registrations, approvals, and ongoing compliance in each market. - **Geographic concentration** [medium] — Most revenue is still derived from China, leaving the business exposed to local demand and policy changes. - **Supplier disruption** [medium] — The company uses advance payments for raw materials and trading products, creating dependency on supplier performance. - Regulatory risk from medical device approvals and compliance - Credit risk from extended customer payment terms - Quality risk if products fail objection or testing standards - Execution risk in building overseas distribution - Supply-chain risk from sourcing raw materials and trading products ## Accounting Revenue is recognized on sales of self-manufactured masks and medical devices, which makes shipment, acceptance, and quality-objection periods important to reported timing. The company also carries credit-loss allowances and supplier prepayments, so estimates around collectability and recoverability can materially affect receivables, expenses, and working capital presentation. - **Revenue recognition timing** — Can shift revenue between periods - **Expected credit losses** — Affects accounts receivable and bad-debt expense - **Supplier advances** — Can create write-downs or expense recognition - Point-in-time revenue recognition on product sales - Quality objection periods can affect revenue timing - Allowance for credit losses on receivables - Prepayments to suppliers require recoverability judgment - Quarterly mix shifts between China and overseas affect comparability --- *Last updated: 2026-09-28T12:18:41.126851+00:00*